NASDAQ:BLRX - BioLineRx Ltd.
$0.30
 $0.00
0.00%
4:00PM EDT
2019-07-15
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BLRX     avg for
industry  
  avg for
sector  
42 stocks weight:  1. 69   114. 77   204. 78  
42 stocks rank:  4. 43 K 1. 44 K 810. 33  
# analyst opinions:  4. 00   13. 59   13. 86  
mean recommendation:  1. 70   2. 12   2. 04  

quick ratio:  5. 05   5. 48   1. 89  
current ratio:  5. 12   5. 85   2. 40  

target price low:  0. 20   82. 72   115. 11  
target price avg:  0. 28   104. 42   138. 02  
target price high:  0. 30   130. 64   159. 47  
1-yr high:  1. 45   110. 27   142. 72  
last close:  0. 30   85. 12   126. 54  
50-day avg:  0. 35   86. 06   122. 35  
200-day avg:  0. 55   88. 76   121. 75  
1-yr low:  0. 30   69. 26   100. 63  
volume:  478. 24 K 3. 51 M 5. 53 M
50-day avg volume:  860. 94 K 3. 21 M 4. 22 M
200-day avg volume:  1. 12 M 3. 04 M 4. 75 M

1-day return:  -0. 73 % -0. 30 % -1. 01 %
this week return:  -10. 18 % -2. 16 % -1. 35 %
12-wk return:  -20. 82 % 3. 34 % 8. 69 %
52-wk return:  -67. 05 % -1. 76 % 12. 22 %

enterprise value (EV):  13. 90 M 46. 50 B 123. 99 B
market cap:  45. 92 M 40. 77 B 109. 11 B
EBITDA:  -24. 03 M 4. 33 B 8. 19 B
enterprise multiple (EV/EBITDA):  -0. 58   5. 45   12. 05  
total debt:  10. 69 M 11. 27 B 17. 58 B
debt/equity:  23. 29   57. 36   120. 25  
net income (common):  -22. 92 M 2. 13 B 4. 27 B

shares outstanding:  146. 55 M 551. 08 M 1. 24 B
shares:  114. 09 M 559. 41 M 1. 22 B
shares short:  2. 01 M 11. 15 M 11. 94 M
shares short prior month:  2. 21 M 9. 31 M 11. 96 M
short ratio:  3. 85   5. 72   3. 43  
total cash/share:  0. 28   11. 00   9. 23  
total cash:  40. 61 M 6. 03 B 6. 01 B
free cash flow:  -22. 99 M 3. 02 B 4. 96 B
operating cash flow:  -22. 01 M 3. 92 B 5. 99 B

book value:  0. 32   13. 02   27. 49  
price/book:  0. 95   4. 21   8. 80  
operating margins:  0. 00 % -380. 20 % -38. 44 %
EBITDA margins:  0. 00 % 13. 59 % 23. 24 %
profit margins:  0. 00 % 10. 94 % 14. 00 %
gross margins:  0. 00 % 36. 11 % 55. 16 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 50 % 1. 08 %

1-yr EPS:  -0. 20   2. 12   4. 26  
forward EPS:  -0. 17   3. 47   7. 14  
P/E:  -1. 51   2. 15   33. 17  
forward P/E:  -1. 77   -4. 03   17. 60  
PE/G:  0. 05   0. 54   0. 34  
growth:  -33. 08 % 263. 03 % 78. 34 %
earnings high:  -0. 04   0. 91   1. 70  
earnings avg:  -0. 04   0. 71   1. 58  
earnings low:  -0. 05   0. 48   1. 46  
revenue high:  250. 00 K 2. 64 B 11. 26 B
revenue avg:  120. 00 K 2. 58 B 11. 09 B
revenue low:  -0. 00   2. 54 B 10. 90 B
return on assets:  -24. 82 % -2. 31 % 5. 31 %
return on equity:  -48. 30 % -82. 48 % 135. 30 %

beta (1yr vs S&P500):  0. 62   1. 26   0. 91  
sharpe (1yr):  -1. 03   0. 07   0. 77  

held % insiders:  3. 46 % 6. 08 % 3. 31 %
held % institutions:  27. 13 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : BLRX
.    100.682 =       100.682 :: --> INITIAL WEIGHT <--
.    - 0.199 =       100.483 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.983 =       199.265 :: P/E factor
.    x 2.163 =       430.969 :: PE/G factor
.     x 1.72 =       741.443 :: beta factor
.    x 0.977 =       724.745 :: sharpe factor
.    x 2.875 =      2083.387 :: current ratio factor
.    x 1.117 =      2326.534 :: quick ratio factor
.    x 1.122 =      2611.259 :: short ratio factor
.    x 1.005 =      2623.623 :: price-to-book factor
.    x 1.186 =      3110.992 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.114 =      6576.589 :: sector+industry 1-year gains factor
.    x 1.033 =      6796.234 :: industry 12-weeks return factor
.    x 1.305 =      8870.946 :: industry 2-weeks return factor
.    x 0.966 =      8568.437 :: "drift" penalty 1 days ago
.    / 2.044 =      4192.473 :: overall "drift" factor
.    x 0.691 =      2897.938 :: largest single-day jump factor
.    x 0.059 =       171.688 :: low price factor
.    x 0.091 =        15.592 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.     x 0.17 =         2.651 :: forward EPS factor
.    x 0.698 =         1.851 :: forward P/E factor
.    x 1.182 =         2.189 :: industry recommendation factor
.    x 2.442 =         5.345 :: company recommendation factor
.    x 1.008 =         5.385 :: factor historical industry gain for week 28
.    x 0.912 =         4.909 :: target low factor
.     x 0.96 =         4.715 :: target mean factor
.    x 0.998 =         4.707 :: target high factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         1.473 :: reduced for readability
.     + 0.22 =         1.693 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      1.693 :: FINAL WEIGHT for NASDAQ:BLRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org